CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Percutaneous Coronary Intervention Readmissions Where Are the Solutions? Can the Vanishing Stent Reappear? Fix the Technique, or Fix the Device? Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)he management of patients with) Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry Causes of Mortality After Percutaneous Coronary Intervention: Insights From the VA Clinical Assessment, Reporting, and Tracking Program Impact of Coronary Lesion Complexity in Percutaneous Coronary Intervention: One-Year Outcomes From the Large, Multicentre e-Ultimaster Registry

Clinical Trial26 Sep 2019

JOURNAL:Circulation. Article Link

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial

S Windecker , RD Lopes, AUGUSTUS Investigators et al. Keywords: antithrombotic therapy; atrial fibrillation; ACS patients; safety and efficacy

FULL TEXT PDF